Cdc7/Dbf4 protein kinase is required for the initiation of DNA replication in Saccharomyces cerevisiae. Cdc7/Dbf4 protein kinase is not a cyclin-dependent kinase (CDK), but is regulated in a similar fashion in that the Cdc7 kinase subunit is inactive in the absence of the regulatory subunit Dbf4. In contrast to what is known about CDKs, Cdc7/Dbf4 protein kinase is shown to be an oligomer in the cell in this report. Genetic data that support this claim include interallelic complementation between several cdc7ts alleles and the cdc7T281A allele and also the results of experiments using the two-hybrid system with Cdc7 in both DNA-binding and transactivation domain plasmids. A molecular interaction between two different Cdc7 molecules was shown by using a HA-tagged Cdc7 protein that differs in size from the wild-type Cdc7 protein: an anti-HA antibody immunoprecipitates both proteins in approximately equal stoichiometry. Analysis of the native molecular weight of Cdc7/Dbf4 protein kinase is consistent with oligomerization of the Cdc7 protein in that complexes of about 180 and 300 kDa were found. Oligomers of Cdc7 protein may exist for the purpose of allosteric regulation or to allow phosphorylation of multiple substrate protein molecules.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s004380050833 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The structural basis of Cdc7-Dbf4 kinase dependent targeting and phosphorylation of the MCM2-7 double hexamer.
Nat Commun
May 2022
DNA Replication Group, Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, Du Cane Road, London, W12 0NN, UK.
The controlled assembly of replication forks is critical for genome stability. The Dbf4-dependent Cdc7 kinase (DDK) initiates replisome assembly by phosphorylating the MCM2-7 replicative helicase at the N-terminal tails of Mcm2, Mcm4 and Mcm6. At present, it remains poorly understood how DDK docks onto the helicase and how the kinase targets distal Mcm subunits for phosphorylation.
View Article and Find Full Text PDFA new horizon for the old antibacterial drug clofoctol.
Drug Discov Today
May 2021
University of Lille, Inserm, INFINITE - U1286, Institut de Chimie Pharmaceutique Albert Lespagnol (ICPAL), Faculté de Pharmacie, 3 rue du Professeur Laguesse, BP-83, F-59006, Lille, France.
The synthetic antibacterial drug clofoctol (CFT) has long been used to treat respiratory tract infections in Europe. In recent years, the drug was found to target two biologically important proteins, the Cdc7/Dbf4 protein kinase complex and the mRNA-binding protein cold shock domain containing E1 (CSDE1), also known as upstream-of-N-Ras protein (UNR). These interactions are at the origin of the antitumor activity of CFT, recently evidenced in prostate cancer and neuroglioma.
View Article and Find Full Text PDFMedicinal applications and molecular targets of dequalinium chloride.
Biochem Pharmacol
April 2021
OncoWitan, Lille (Wasquehal) 59290, France. Electronic address:
For more than 60 years dequalinium chloride (DQ) has been used as anti-infective drug, mainly to treat local infections. It is a standard drug to treat bacterial vaginosis and an active ingredient of sore-throat lozenges. As a lipophilic bis-quaternary ammonium molecule, the drug displays membrane effects and selectively targets mitochondria to deplete DNA and to block energy production in cells.
View Article and Find Full Text PDFStructural Basis for the Activation and Target Site Specificity of CDC7 Kinase.
Structure
August 2020
Chromatin Structure and Mobile DNA, The Francis Crick Institute, London NW1 1AT, UK; Division of Medicine, Imperial College London, London W2 1PG, UK. Electronic address:
Article Synopsis
- - CDC7 is a crucial Ser/Thr kinase involved in DNA replication during the S phase of the cell cycle, with its activity regulated by DBF4.
- - Crystal structures of CDC7-DBF4 show how a zinc-finger domain stabilizes the kinase's activation loop, facilitating access to the active site for substrate binding.
- - The study reveals how CDC7 selectively phosphorylates specific Ser/Thr residues, providing insights into its activation by DBF4 and the recognition of its preferred substrates.
Kinome expression profiling to target new therapeutic avenues in multiple myeloma.
Haematologica
March 2020
IGH, CNRS, Université de Montpellier, Montpellier, France
Multiple myeloma (MM) account for approximately 10% of hematological malignancies and is the second most common hematological disorder. Kinases inhibitors are widely used and their efficiency for the treatment of cancers has been demonstrated. Here, in order to identify kinases of potential therapeutic interest for the treatment of MM, we investigated the prognostic impact of the kinome expression profile in large cohorts of patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!